Extrapyramidal	extrapyramidal	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
and	and	O	O	O	O
oral	oral	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
an	an	O	O	O	O
analysis	analysis	O	O	O	O
of	of	O	O	O	O
explanatory	explanatory	O	O	O	O
patient	patient	O	O	O	O
and	and	O	O	O	O
treatment	treatment	O	O	O	O
characteristics	characteristics	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
extrapyramidal	extrapyramidal	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
(	(	O	O	O	O
EPS	eps	O	DISEASE	OTHERS	I
)	)	O	O	O	O
was	was	O	O	O	O
evaluated	evaluated	O	O	O	O
in	in	O	O	O	O
98	98	O	O	O	O
patients	patients	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
of	of	O	O	O	O
parkinsonism	parkinsonism	O	DISEASE	OTHERS	I
was	was	O	O	O	O
higher	higher	O	O	O	O
at	at	O	O	O	O
higher	higher	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
in	in	O	O	O	O
younger	younger	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Prophylactic	prophylactic	O	O	O	O
antiparkinsonian	antiparkinsonian	O	O	O	O
medication	medication	O	O	O	O
was	was	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
younger	younger	O	O	O	O
but	but	O	O	O	O
not	not	O	O	O	O
in	in	O	O	O	O
older	older	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

However	however	O	O	O	O
,	,	O	O	O	O
these	these	O	O	O	O
medications	medications	O	O	O	O
were	were	O	O	O	O
more	more	O	O	O	O
effective	effective	O	O	O	O
in	in	O	O	O	O
both	both	O	O	O	O
young	young	O	O	O	O
and	and	O	O	O	O
old	old	O	O	O	O
patients	patients	O	O	O	O
when	when	O	O	O	O
given	given	O	O	O	O
after	after	O	O	O	O
parkinsonism	parkinsonism	O	DISEASE	OTHERS	I
developed	developed	O	O	O	O
.	.	O	O	O	O

Akathisia	akathisia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
controlled	controlled	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
benzodiazepine	benzodiazepine	CHEMICALS	O	OTHERS	I
lorazepam	lorazepam	O	O	OTHERS	I
in	in	O	O	O	O
14	14	O	O	O	O
out	out	O	O	O	O
of	of	O	O	O	O
16	16	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
prophylactic	prophylactic	O	O	O	O
antiparkinsonians	antiparkinsonians	O	O	O	O
were	were	O	O	O	O
ineffective	ineffective	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
points	points	O	O	O	O
to	to	O	O	O	O
patient	patient	O	O	O	O
characteristics	characteristics	O	O	O	O
that	that	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
of	of	O	O	O	O
significance	significance	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
EPS	eps	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
haloperidol	haloperidol	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

